{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prefilled+syringe&page=2",
    "query": {
      "intervention": "Prefilled syringe",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prefilled+syringe&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T04:21:35.979Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02404350",
      "title": "Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Secukinumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 997,
      "start_date": "2015-08-31",
      "completion_date": "2019-01-24",
      "has_results": true,
      "last_update_posted_date": "2020-04-20",
      "last_synced_at": "2026-09-27T04:21:35.979Z",
      "location_count": 22,
      "location_summary": "Upland, California • Aurora, Colorado • Denver, Colorado + 16 more",
      "locations": [
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02404350"
    },
    {
      "nct_id": "NCT05306275",
      "title": "A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "CSL312",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 132,
      "start_date": "2022-04-04",
      "completion_date": "2022-09-27",
      "has_results": false,
      "last_update_posted_date": "2022-10-06",
      "last_synced_at": "2026-09-27T04:21:35.979Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05306275"
    },
    {
      "nct_id": "NCT02905331",
      "title": "Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Guselkumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2017-02-28",
      "completion_date": "2018-02-06",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-09-27T04:21:35.979Z",
      "location_count": 8,
      "location_summary": "Ocala, Florida • Rolling Meadows, Illinois • Plainfield, Indiana + 5 more",
      "locations": [
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Rolling Meadows",
          "state": "Illinois"
        },
        {
          "city": "Plainfield",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Fort Gratiot",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02905331"
    },
    {
      "nct_id": "NCT01573572",
      "title": "Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Age-Related Macular Degeneration",
        "Retinal Vein Occlusion",
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "pegaptanib sodium injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2010-04-22",
      "completion_date": "2019-11-14",
      "has_results": true,
      "last_update_posted_date": "2021-01-08",
      "last_synced_at": "2026-09-27T04:21:35.979Z",
      "location_count": 4,
      "location_summary": "Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Marshalltown",
          "state": "Iowa"
        },
        {
          "city": "West Mifflin",
          "state": "Pennsylvania"
        },
        {
          "city": "Harlingen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01573572"
    },
    {
      "nct_id": "NCT04394351",
      "title": "Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Esophagitis (EoE)"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "1 Year to 11 Years"
      },
      "enrollment_count": 102,
      "start_date": "2020-09-01",
      "completion_date": "2024-05-14",
      "has_results": true,
      "last_update_posted_date": "2025-10-27",
      "last_synced_at": "2026-09-27T04:21:35.979Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04394351"
    },
    {
      "nct_id": "NCT02792231",
      "title": "Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Multiple Scelrosis"
      ],
      "interventions": [
        {
          "name": "Ofatumumab subcutaneous injection",
          "type": "DRUG"
        },
        {
          "name": "Teriflunomide-matching placebo capsules",
          "type": "DRUG"
        },
        {
          "name": "Teriflunomide capsule",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo of ofatumumab subcutaneous injections",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 955,
      "start_date": "2016-08-26",
      "completion_date": "2020-10-22",
      "has_results": true,
      "last_update_posted_date": "2021-11-22",
      "last_synced_at": "2026-09-27T04:21:35.979Z",
      "location_count": 59,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Basalt",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02792231"
    },
    {
      "nct_id": "NCT01870986",
      "title": "Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-06410293",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Humira (adalimumab-EU)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Humira (adalimumab-US)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 210,
      "start_date": "2013-05",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2014-02-14",
      "last_synced_at": "2026-09-27T04:21:35.979Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01870986"
    },
    {
      "nct_id": "NCT03949621",
      "title": "A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Vedolizumab SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2018-02-06",
      "completion_date": "2018-08-13",
      "has_results": true,
      "last_update_posted_date": "2019-11-13",
      "last_synced_at": "2026-09-27T04:21:35.979Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03949621"
    },
    {
      "nct_id": "NCT02405442",
      "title": "Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Andecaliximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 187,
      "start_date": "2015-04-30",
      "completion_date": "2016-12-22",
      "has_results": true,
      "last_update_posted_date": "2019-04-23",
      "last_synced_at": "2026-09-27T04:21:35.979Z",
      "location_count": 33,
      "location_summary": "Dothan, Alabama • Scottsdale, Arizona • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02405442"
    },
    {
      "nct_id": "NCT01147341",
      "title": "Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Cimzia",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael Schiff, MD",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 37,
      "start_date": "2010-07",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2014-06-09",
      "last_synced_at": "2026-09-27T04:21:35.979Z",
      "location_count": 12,
      "location_summary": "Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147341"
    }
  ]
}